Two of DSM’s probiotic strains have received New Dietary Ingredient status from FDA, according to a press release.

Lactobacillus rhamnosus19070-2 andLactobacillus reuteri12246-CU are already commercially available in Europe, Asia, and the Middle East, and with the no-objection NDI status, are now available in the U.S.

“The NDI status of our two flagship strains strengthens confidence in our science-based ingredients and creates a multitude of opportunities for our US-based customers to remain at the forefront of the market,” says Penny Antonopoulos, Director Dietary Supplements, Human Nutrition & Care, North America, DSM. “Both strains were identified as among the best performing probiotic varieties—out of a total of 47—by a large and comprehensive screening program. Both strains, for example, demonstrated excellent pH tolerance and adhesion properties to enable passage through the gastrointestinal tract and strong antimicrobial activity against pathogenic bacteria. Because of this, the strains were specifically chosen to support customers looking to innovate in the gut health space across a number of applications.”

DSM’s Consumer Health Concerns Study 2021 surveyed nearly 19,000 consumers across 24 countries, and revealed that 61% of consumers are concerned about their gut health, and 67% of those respondents take action to support it.

Related: DSM Commits to Addressing Social, Environmental Challenges Surrounding Food Industry Members Call FDA Inaction “Disheartening” Update! Digestive Health Category

“Our growing global presence in the gut health market signifies our continued investment in this trending category, where growth is driven by changing consumer mindsets,” says Jill Porter, Global Director Gut Health, Dietary Supplements, DSM. “Customers can trust that DSM will help them navigate the developing science and awareness around holistic gut health—enabling them to bring targeted health solutions to market faster. We’ve already developed a number of inspiring product concepts with strong consumer appeal, to demonstrate how customers can leverage our DSM strains as part of our industry-leading portfolio to develop 100% finished, health benefit-driven solutions packed with purpose.”